<DOC>
	<DOC>NCT02288975</DOC>
	<brief_summary>The aim of the study is to investigate the effect of CytoSorb® treatment within the first 48 hours of septic shock on organ dysfunction, microcirculation and on the cytokine storm as monitored by leukocyte activation and inflammatory mediators.</brief_summary>
	<brief_title>Adsorbtion of Cytokines Early in Septic Shock: the ACESS Study</brief_title>
	<detailed_description />
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Shock, Septic</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<criteria>Signs of hypoperfusion: serum lactate &gt;2 mmol/L, low central venous oxygen saturation (ScvO2) (&lt;70%) or high ScvO2 (&gt;85%), metabolic acidosis, oligoanuria, high venoustoarterial CO2gap (dCO2 &gt;6 mm Hg) Hemodynamic support with vasopressors Procalcitonin level ≥ 3 ng/ml Invasive hemodynamic monitoring Written informed content Patients under 18 years Pregnancy (bHCG test positivity) Surgical intervention in context with the septic insult New York Heart Association IV heart failure Acute coronary syndrome Need for acute or chronic hemodialysis Acute haematological malignancies Cardiogenic shock Post cardiopulmonary resuscitation care Immunosuppression, systemic steroid therapy (&gt;10mg prednisolon/day) Human immunodeficiency virus infection (HIV) and active AIDS Patients with donated organs Thrombocytopenia (&lt;20.000/ml) More than 10%of body surface area with third degree burn</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hemoadsorption</keyword>
	<keyword>extracorporeal blood purification</keyword>
	<keyword>CytoSorb</keyword>
	<keyword>hemofiltration</keyword>
	<keyword>SIRS</keyword>
	<keyword>sepsis</keyword>
	<keyword>septic shock</keyword>
	<keyword>membranes</keyword>
	<keyword>ICU</keyword>
	<keyword>dialysis</keyword>
	<keyword>adsorption</keyword>
</DOC>